Piper Sandler reports Immunic will be presenting four abstracts at ECTRIMS, which is taking place September 18-20 and is “one of the main conferences for the MS space.” Full abstracts are not yet out, but regular abstracts will be published on September 4, according to the conference website, the analyst noted. The firm, which calls Immunic “an under-the-radar name despite having a robust Vidofludimus Calcium program,” maintains an Overweight rating and $28 price target on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMUX:
- Immunic appoints Jason Tardio as COO
- Immunic’s (IMUX) IMU-838 Program: Current Status and the Road Ahead
- Immunic Stock (IMUX): Deep Dive into Lead Candidate, Vidofludimus Calcium
- Immunic Stock (IMUX): Striving to Develop Innovative Therapies
- Immunic to Participate in Industry and Scientific Conferences in June